Your browser doesn't support javascript.
loading
Base editing screens map mutations affecting interferon-γ signaling in cancer.
Coelho, Matthew A; Cooper, Sarah; Strauss, Magdalena E; Karakoc, Emre; Bhosle, Shriram; Gonçalves, Emanuel; Picco, Gabriele; Burgold, Thomas; Cattaneo, Chiara M; Veninga, Vivien; Consonni, Sarah; Dinçer, Cansu; Vieira, Sara F; Gibson, Freddy; Barthorpe, Syd; Hardy, Claire; Rein, Joel; Thomas, Mark; Marioni, John; Voest, Emile E; Bassett, Andrew; Garnett, Mathew J.
Affiliation
  • Coelho MA; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK; Open Targets, Cambridge, UK.
  • Cooper S; Gene Editing and Cellular Research and Development, Wellcome Sanger Institute, Hinxton, UK; Open Targets, Cambridge, UK.
  • Strauss ME; EMBL-European Bioinformatics Institute, Cambridge, UK.
  • Karakoc E; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK; Open Targets, Cambridge, UK.
  • Bhosle S; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK.
  • Gonçalves E; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK; Instituto Superior Técnico, Universidade de Lisboa, 1049-001, and, INESC-ID, 1000-029, Lisbon, Portugal.
  • Picco G; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK; Open Targets, Cambridge, UK.
  • Burgold T; Gene Editing and Cellular Research and Development, Wellcome Sanger Institute, Hinxton, UK.
  • Cattaneo CM; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Open Targets, Cambridge, UK.
  • Veninga V; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Open Targets, Cambridge, UK.
  • Consonni S; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK; Open Targets, Cambridge, UK.
  • Dinçer C; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK.
  • Vieira SF; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK; Open Targets, Cambridge, UK.
  • Gibson F; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK.
  • Barthorpe S; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK.
  • Hardy C; Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Hinxton, UK.
  • Rein J; Cellular Operations and Stem Cell Informatics, Wellcome Sanger Institute, Hinxton, UK.
  • Thomas M; Cellular Operations and Stem Cell Informatics, Wellcome Sanger Institute, Hinxton, UK.
  • Marioni J; EMBL-European Bioinformatics Institute, Cambridge, UK.
  • Voest EE; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Open Targets, Cambridge, UK.
  • Bassett A; Gene Editing and Cellular Research and Development, Wellcome Sanger Institute, Hinxton, UK; Open Targets, Cambridge, UK.
  • Garnett MJ; Translational Cancer Genomics, Wellcome Sanger Institute, Hinxton, UK; Open Targets, Cambridge, UK. Electronic address: mathew.garnett@sanger.ac.uk.
Cancer Cell ; 41(2): 288-303.e6, 2023 02 13.
Article in En | MEDLINE | ID: mdl-36669486
ABSTRACT
Interferon-γ (IFN-γ) signaling mediates host responses to infection, inflammation and anti-tumor immunity. Mutations in the IFN-γ signaling pathway cause immunological disorders, hematological malignancies, and resistance to immune checkpoint blockade (ICB) in cancer; however, the function of most clinically observed variants remains unknown. Here, we systematically investigate the genetic determinants of IFN-γ response in colorectal cancer cells using CRISPR-Cas9 screens and base editing mutagenesis. Deep mutagenesis of JAK1 with cytidine and adenine base editors, combined with pathway-wide screens, reveal loss-of-function and gain-of-function mutations, including causal variants in hematological malignancies and mutations detected in patients refractory to ICB. We functionally validate variants of uncertain significance in primary tumor organoids, where engineering missense mutations in JAK1 enhanced or reduced sensitivity to autologous tumor-reactive T cells. We identify more than 300 predicted missense mutations altering IFN-γ pathway activity, generating a valuable resource for interpreting gene variant function.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Hematologic Neoplasms / Neoplasms Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: United kingdom

Full text: 1 Database: MEDLINE Main subject: Hematologic Neoplasms / Neoplasms Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: United kingdom